Revelation Biosciences, Inc.

What they do

Revelation Biosciences is a clinical-stage life sciences company based in San Diego, California, focused on rebalancing inflammation using its proprietary formulation Gemini. Gemini is a formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic TLR4 agonist that modulates the innate immune response. The company's lead programs are GEM-AKI for acute kidney injury and GEM-CKD for chronic kidney disease, with additional potential programs in burn injury and post-surgical infection. It has no approved products and has never generated revenue from product sales.

Revenue drivers

• No approved products — The company has no commercial products and has never generated revenue from product sales; it has funded operations through equity issuances.
• GEM-AKI (acute kidney injury) — Lead product candidate, currently in Phase 2/3 clinical trial start-up; potential market is large, but no commercialization expected for several years.
• GEM-CKD (chronic kidney disease) — Preclinical/clinical stage program; part of pipeline but no revenue yet.

Recent performance

For the six months ended June 30, 2026, the company reported a net loss of $6.3 million, compared to $4.5 million in the prior-year period. As of June 30, 2026, cash and cash equivalents were $11.5 million, up from $10.7 million at December 31, 2025. The company raised approximately $6.7 million in net proceeds in January 2026 from a warrant inducement transaction. Annual net losses have ranged from $8.9 million (2025) to $15.0 million (2024). The company has an accumulated deficit of $55.8 million as of June 30, 2026.

Strategy

Management plans to advance GEM-AKI into a Phase 2/3 clinical trial, with enrollment targeted to start by year-end 2026. The company aims to build its pipeline around kidney care and may seek out-licensing or academic collaborations to expand Gemini's applications. It plans to raise additional capital through public or private equity or debt financings to fund operations. Management may delay, reduce, or terminate programs if sufficient funding is not obtained.

Risks

• Going concern risk — Management has stated that current cash and cash equivalents are not sufficient to sustain operations for one year after the issuance of financial statements, raising substantial doubt about the company's ability to continue as a going concern.
• No revenue and recurring losses — The company has never generated revenue and has incurred recurring net losses since inception, with an accumulated deficit of $55.8 million as of June 30, 2026.
• Clinical and regulatory risk — As a clinical-stage company, there is no guarantee that GEM-AKI or GEM-CKD will demonstrate adequate efficacy or safety, gain regulatory approval, or become commercially viable.
• Capital needs — The company may be unable to raise additional funds on acceptable terms, which could force it to delay, reduce, or eliminate its development programs.

Outlook

Management expects to continue incurring operating losses and negative cash flows for the foreseeable future. Based on current plans, the company believes its cash is sufficient to fund operations through the first quarter of 2027. Start-up activities for the Phase 2/3 AKI trial are progressing, and management aims to begin enrollment by year-end 2026. The company plans to seek additional funding through financings or collaborations.